Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Avidity Biosciences Inc shares valued at $105,015 were sold by Hughes Steven George on Oct 22 ’25. At $47.54 per share, Hughes Steven George sold 2,209 shares. The insider’s holdings dropped to 38,867 shares worth approximately $2.71 million following the completion of this transaction.
Also, McCarthy Teresa sold 20,000 shares, netting a total of over 1,003,058 in proceeds. Following the sale of shares at $50.15 each, the insider now holds 97,130 shares.
Before that, Mosbrooker Eric had sold 6,562 shares from its account. In a trade valued at $297,771, the Chief Commercial Officer traded Avidity Biosciences Inc shares for $45.38 each. Upon closing the transaction, the insider’s holdings decreased to 6,562 shares, worth approximately $3.83 million.
As published in their initiating research note from Roth Capital on September 17, 2025, Avidity Biosciences Inc [RNA] has been a Buy and the price target has been revised to $62. As of June 24, 2025, Bernstein has initiated its “an Outperform” rating for RNA. Earlier on June 17, 2025, Wolfe Research initiated its rating. Their recommendation was “an Outperform” for RNA stock.
Analyzing RNA Stock Performance
On last trading session, Avidity Biosciences Inc [NASDAQ: RNA] plunged -0.40% to $69.65. The stock’s lowest price that day was $69.65, but it reached a high of $69.95 in the same session. During the last five days, there has been a surge of approximately 48.63%. Over the course of the year, Avidity Biosciences Inc shares have jumped approximately 54.40%. Shares of the company reached a 52-week high of $70.51 on 10/27/25 and a 52-week low of $21.51 on 04/09/25.
Support And Resistance Levels for Avidity Biosciences Inc (RNA)
According to the 24-hour chart, there is a support level at 69.53, which, if violated, would cause prices to drop to 69.40. In the upper region, resistance lies at 69.87. The next price resistance is at 70.08. RSI (Relative Strength Index) is 79.55 on the 14-day chart, showing overbought technical sentiment.
Is Avidity Biosciences Inc subject to short interest?
Stocks of Avidity Biosciences Inc saw a sharp steep in short interest on 2025-10-15 dropping by -2.21 million shares to 20.03 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 22.24 million shares. A decline of -11.06% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.61 of the overall float, the days-to-cover ratio (short ratio) decline to 8.61.
Which companies own the most shares of Avidity Biosciences Inc (RNA)?
In terms of Avidity Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, up nearly 2.96% from the previous closing price of $69.93. Analysts anticipate Avidity Biosciences Inc stock to reach 96 by 2025, with the lowest price target being 70. In spite of this, 6 analysts ranked Avidity Biosciences Inc stock as Buy at the end of 2025. On June 11, 2025, Raymond James assigned a price target of “a Strong buy” to the stock and initiated coverage with a $65.
